WELCOME to: 'Stu's Views and MS News' an informational archive provided by MS Views and News

· Key-Note: This blog provides education, information and resources to benefit those affected by Multiple Sclerosis.

· Opt-In at our website (MS Views and News) to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries.

· Our live MS educational seminars average 67 people per educational program. SINCE our first program in February 2010, we have hosted more than 130 educational programs.

· WATCH OUR Multiple Sclerosis archived MS EDUCATIONAL VIDEOS by Topic. Click: www.youtube.com/msviewsandnews

Be Empowered with Beneficial MS Information - ---Visit MS Views and News.org

Scroll to view all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information.

===================================================================

Sunday, March 24, 2013

Oral Laquinimod for Multiple Sclerosis Passes Phase 3 Extension




Teva Pharmaceutical and Active Biotech announced top-line results from an open-label extension of the Phase 3 ALLEGRO study, which assessed the progression of disability and safety of oral laquinimod in early vs. delayed-start relapsing remitting multiple sclerosis (RRMS) patients. Laquinimod is an oral, once-daily CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of MS.
The study compared the effectiveness of laquinimod in patients who received 36 months (early-start) vs. those who received 24 months of laquinimod treatment (delayed-start). Out of the 864 RRMS patients who participated in the original double-blind ALLEGRO trial, 97% enrolled in the open-label extension and 87% completed one year of the open-label phase.
During the entire duration of the study (double blind and open label phase), early start patients were less likely to experience disease progression than those with a delayed start of laquinimod (11.8% risk of confirmed disability progression vs. 16.7%, HR = 0.62, P< 0.0038).
For more information call (215) 591-3000 or visit www.tevapharm.com or www.activebiotech.com.

Article source: empr.com 
..



USE OUR SHARE LINKS at the top of this page  - to provide this article to others

If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left

REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register


.

No comments: